

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.:	09/436,347	Group Art Unit:	1643
Confirmation No.:	6491	Examiner:	A. M. Harris
Filed:	November 9, 1999		
Inventors:	Christine A. WHITE et al.		
For:	Treatment of Chronic Lymphocytic Leukemia using Anti-CD20 Antibodies (as amended)		

Mail Stop **Amendment AF**
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with the requirements and provisions of 37 C.F.R. §§ 1.56, 1.97, and 1.98, applicant cites documents listed on the Form PTO-1449 that accompanies this paper. Copies of the documents, other than U.S. patent documents, are provided. In accordance with 37 C.F.R. § 1.98(d) only copies of patents, publications, or other information not previously submitted in a earlier application are provided.

Applicant does not represent that a search has been conducted, that the cited documents are material to the examination of the present patent application or that the cited documents are prior art against the claims in this application.

This disclosure statement is filed under the provisions of 37 C.F.R. § 1.97(b)(4), before the mailing of a first Office action after the filing of a request for continued examination. Although no fee is believed to be due, the Director is authorized to charge any fees that may be required to make this submission timely or proper to our Deposit Account **No. 18-1260**.

* * *

Respectfully submitted,

/David L. Devernoe/

David L. Devernoe, Reg. No. 50,128
Attorney for Biogen Idec Inc.

SIDLEY AUSTIN LLP
1501 K Street, N.W.
Washington, DC 20005
tel. (202) 736-8143
fax (202) 736-8711
Customer No.: 47553

Date: June 29, 2009